No Result
View All Result
  • Login
  • Register
Business & Technology
SUBSCRIBE
  • .
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
  • .
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
No Result
View All Result
Biztech Asia
Home Thought Leadership

Vaccines breakthroughs call for cautious optimism

by editorial
12/11/20
in Thought Leadership
5 min read
0
Vaccines breakthroughs call for cautious optimism

By Ameen Kamal, Head of Science & Technology at EMIR Research,

News of a vaccine breakthrough from Pfizer Inc. and BioNTech SE on its mRNA-type BNT162b2 vaccine achieving 90% effectiveness have stirred positive reactions as many see this as a significant light at the end of the tunnel. The pandemic has hit the economy very severely and people (and the market) deserve this ray of hope.

Russia’s Sputnik V vaccine by Gamaleya Research Institute followed suit claiming a staggering 92% effectiveness. It’s reasonable to assume that the timing of Sputnik V press release came as response to Pfizer-BioNTech’s announcement. As Malaysia is reportedly prepping to make advanced purchase of vaccines, the public or even geopolitical sentiments – no matter how significant it may seem – must not influence a populist, or sentiment-driven decision-making for policy makers.

Claims of 90% or 92% effectiveness are really good given the 50% efficacy bar by the U.S. Food and Drug Administration (USFDA). As mentioned by Matthew Herper, Senior Writer for Medicine at STAT – a US-based health news site – expert projections of Covid-19 vaccine effectiveness was around 60% – 70%. Therefore, these claimed efficacies are better than what most had expected.

However, the efficacy rate may change for both vaccines as the respective clinical trials continue. Referring to Pfizer-BioNTech vaccine, health and science correspondent James Gallagher mentioned the absence of full clinical trial results which have yet to be published in medical journals to be peer-reviewed – which could also be the case with Sputnik V according to its press release.

Gallagher raised a similar concern as EMIR Research by alluding to immunity retainment as the ‘biggest question’, and that it may take a long time to be elucidated. High-efficacy vaccines can still be undermined by short retainment of immunity – complicating vaccination efforts, and further pressuring the already-stretched supply chains for new batches faster than expected. Chinese authorities have reportedly lowered the immunity retainment bar to 6 months.

Immunity retainment, any potential long-term side effects, and long-term safety of novel adjuvants (vaccine mixture compounds), if any, need a longer time to be determined. The Sputnik V press release alludes to the ability to provide “long-term immune response after the second injection”. Pfizer is perhaps more prudent to not make such claims yet, and mentioned that participants will continue to be monitored for an additional two years after the second dose, while the Sputnik V press release indicated only six months.

It is worth noting however, that unlike Pfizer-BioNTech vaccine, Sputnik V has been given emergency use ‘authorisation mechanism’ to allow it to be administered to high-risk groups. Success would confer a real-world data advantage over competitors, despite being an arguably risky move.

If Malaysia would call for emergency use of such vaccines – and therefore taking a higher risk than in normal circumstances – it is imperative to also conduct a similar monitoring on the Malaysia population to determine parameters such as immunity retainment, safety, efficacy, and efficiency.

It is also important to note that the unprecedented speed by which vaccines are being developed. The pandemic hasn’t even reached one year, and already we have vaccines in Phase 3 clinical trials with above 90% effectiveness, and with both vaccines claiming no serious safety or adverse concerns thus far.

Understandably, there may be a concern that lucrative market prospects and geopolitics may pressure any parties to cut corners. Therefore, thorough assessment by local authorities is crucial despite pressures of socio-economy and geopolitics.

According to World Economic Forum senior writer Douglas Broom, vaccine discovery to approval, in general, can take about ten years. This is attributed to the nature of the entire scientific process that is naturally time consuming, resource intensive, and is subject to stringent requirements set by regulatory bodies for approval.

Vaccine development is also plagued with high failure rate – about 93% of vaccine candidates fail from the stage of animal testing to successful vaccine registration, as mentioned by Jerome Kim, director-general of the International Vaccine Institute when speaking to CNBC.

New technologies and vast resources have undoubtedly sped up the process, but the fact is that mRNA vaccines are novel, never approved before and haven’t been tested for very long. On the other hand, Sputnik V vaccine is claimed to be “based on a well-studied human adenoviral vector platform that had proven safe and effective with no long-term side effects”. Nevertheless, cautious optimism is reasonable for both.

Also, how much of the demographics tested in the clinical trials of both vaccines are relevant, and therefore, can be extrapolated to Malaysia population?

Long-term effects for novel mRNA vaccines are relatively a much bigger unknown as this is not yet sufficiently established in the Pfizer-BioNTech Phase 3 trials that started on July 27. Proponents of Sputnik V appears to tout the “well-studied human adenoviral vector platform”, alluding to higher levels technology familiarity, track record, and therefore, safety. Needless to say, this has to be backed up with full trial reports and longer tests.

In any case, EMIR Research noted previously that these metrices and uncertainties are likely to be reflected in prices and various legal wordings in contracts, especially ‘advanced purchase’ ones. So Malaysian authorities must review these carefully, regardless of public sentiment.

Relatedly, Malaysia also has no experience for production and related supply chain experience for any Covid-19 vaccine candidates, as it would have if Malaysia participated in producing doses needed for clinical trials. Understandably, the concern may be higher for the more novel types of vaccines such as BNT162b2 by Pfizer-BioNTech.

As for logistical challenges, EMIR Research has previously highlighted that according to Fierce Pharma associate editor Kyle Blankenship, BNT162b2 was reportedly requiring temperatures of -70 degrees Celsius for longer-term storage and at refrigerated temperatures for up to two days.

Such operating parameters may limit vaccination to be conducted at sites with specialised equipment, by trained personnel and for a very limited duration per vaccination event.

Gallagher opined similarly by mentioning “massive manufacturing and logistical challenges in immunising huge numbers of people, as the vaccine has to be kept in ultra-cold storage at – 80Cº”. According to Herper, Pfizer is confident in the manageability of these issues.

Should this vaccine be one of Malaysia’s choice, the country requires ultra-cold chains in handling the movement and storage of such vaccines and properly trained personnel – especially in nation-wide vaccination efforts. As reported by Reuters, this may present a significant challenge for regions where a combination of high temperatures and insufficient infrastructure (such as in Asia) can make it difficult to maintain the cold chain when moving vaccines.

Comparatively, Blankenship mentioned Moderna – another company pursuing mRNA vaccine – as reportedly requiring -20 degrees Celcius for storage and if so, may confer a logistical advantage. This could be similar to Sputnik V’s “no higher than -18 degrees Celcius” storage requirement as alluded to by author Kostadin Fikiin in a Euractive article. Blankenship also mentioned other types of vaccines by other companies that may be held for months at refrigerated temperatures.

Accordingly, it’s reasonable to assume that specialised equipment and a higher-level of care would be needed in handling fill-and-finish for the more temperature-sensitive types. Whichever is Malaysia’s decision, this must be addressed early-on.

More results are expected by the end of this year and probably in the first quarter of 2021, which should provide more insights on the performance of these vaccines. Therefore, before putting all bets on one vaccine, thorough comparative assessment between different vaccines should be conducted.

Nevertheless, findings thus far from Pfizer-BioNTech and Gamaleya Research Institute’s Sputnik V vaccine appear to be big wins for science, a much-needed hope for the people and is a cause for applause – but with cautious optimism, and not yet to shoot fireworks.

Previous Post

The largest national budget on record – can the economy get back on track?

Next Post

Chinese tech bloodbath

editorial

editorial

Related Posts

Are bad PCR practices churning out false positive Covid-19 cases?
Thought Leadership

A vaccination race between nations can have no winners

The Big Picture: Boats afloat
Thought Leadership

The Big Picture: Boats afloat

Comprehensive measures required to win Malaysia’s pandemic war
Thought Leadership

Comprehensive measures required to win Malaysia’s pandemic war

IKEA fits in a world that wants to buy less, says Ingka Group’s CEO
Thought Leadership

IKEA fits in a world that wants to buy less, says Ingka Group’s CEO

The how of adopting blockchain route for the halal meat industry
Thought Leadership

The how of adopting blockchain route for the halal meat industry

How to build more resilient countries after the COVID-19 pandemic
Thought Leadership

How to build more resilient countries after the COVID-19 pandemic

Next Post
Chinese tech bloodbath

Chinese tech bloodbath

Petronas marks start up business for LNG bunkering with completion of first delivery

Petronas marks start up business for LNG bunkering with completion of first delivery

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

I agree to the Terms & Conditions and Privacy Policy.

Recommended Stories

Nokia to deploy first commercial 5G standalone for enterprise customers

Nokia to deploy first commercial 5G standalone for enterprise customers

Aussie dollar set to strengthen in 2021

Aussie dollar set to strengthen in 2021

Instapay partners with Mastercard to cater to underbanked community

Instapay partners with Mastercard to cater to underbanked community

Popular Stories

  • Economic recovery: an elusive thought?

    Economic recovery: an elusive thought?

    0 shares
    Share 0 Tweet 0
  • Cannibalising your business can be profitable

    0 shares
    Share 0 Tweet 0
  • Sexual fulfillment builds confidence and well-being

    0 shares
    Share 0 Tweet 0
  • Tech Stocks – Ant gets stomped on but REITS offer stability amid volatility

    0 shares
    Share 0 Tweet 0
  • Singapore REITS and China tech stocks – Which should you buy?

    0 shares
    Share 0 Tweet 0

About Us

A Business and Technology digital publication that engages business leaders in business and technology conversations to help everyone pivot, adapt, and thrive in these turbulent times.

LEARN MORE »

Contact Us

Phone: 016-2011 050

Email: editor@biztech.asia

Address:
Level 18, Boutique Office 1 (B01-C)
Menara 2, No. 3, Jalan Bangsar,
KL Eco City, 59200, Kuala Lumpur.

Email Newsletter

Loading

© 2020 Business & Technology - made possible by Milestones Digital.

No Result
View All Result
  • Home
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
  • Login
  • Sign Up

© 2020 Business & Technology - made possible by Milestones Digital.

Welcome Back!

Sign In with Facebook
Sign In with Google
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Google
OR

Fill the forms bellow to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

will use the information you provide on this form to be in touch with you and to provide updates and marketing.